Targets › HSPG2
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.
Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. (UniProt, P98160)
Open in Phaseline: the race on HSPG2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Tennessee Graduate School of Medicine | 99mTc-p5+14 Pan-amyloid reactive peptide that binds hypersulfated heparan sulfate glycosaminoglycans a | HSPG2 | Phase 1 | Systemic Amyloidosis | Dec 2026 |
Systemic Amyloidosis (1)
mixed (1)
University of Tennessee Graduate School of Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.